The study investigated patients using Orthofix’s SpinalStim bone growth therapy device experienced less pain as well as increased function and quality of life, according to a Dec. 21 news release from Orthofix.
Conducted at 10 centers in the U.S., the study included a total of 142 patients with one or more risk factors for pseudarthrosis. The patients used SpinalStim for six months after the procedure and over 82 percent experienced a successful fusion.
The study was published in the International Journal of Spine Surgery, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
